Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#4385 SDHB-related metastatic paragangliomas treated with capecitabine and temozolomide: Experience of a tertiary centre

Introduction: SDHB pathogenic variants predispose to aggressive and metastatic paragangliomas (mPGLs). International consensus recommends temozolomide treatment (low-grade evidence). Capecitabine and temozolomide (CAPTEM) has shown advantage over temozolomide in the treatment of neuroendocrine tumours (NETs). Evidence for its use in mPGLs remains scarce.

Conference:

Presenting Author: G. Martins R

Authors: Silva L, Martins R, Couto J, Garcia R, Martins Fernandes A,

Keywords: mPGL, SDHB, captem,

#4170 Analysis of the efficacy of STEM chemotherapy in patients with metastatic paraganglioma

Introduction: Paraganglioma is a special kind of neuroendocrine tumor, located outside the adrenal gland, about 35-40% is related to heredity and has corresponding germline mutation. The therapeutic response is different from that of neuroendocrine tumors derived from gastrointestinal and pancreas.

Conference:

Presenting Author: Tan H

Authors: Tan H, Zhao H, Shi S, Jiang L, Chi Y,

Keywords: metastatic paraganglioma, STEM, efficacy,

#3985 Comparison of the diagnostic value of 68Ga-DOTANOC, 18F-FDOPA, and18F-FDG PET/CT for metastatic paraganglioma

Introduction: Functional imaging is important for precise treatment for metastatic paraganglioma (PGL).

Conference:

Presenting Author: Xu J

Authors: Bian L, Xu J, Xu X, Chen J, Song S,

Keywords: paraganglioma, 18F-FDG, 68Ga-DOTANOC, 18F-DOPA, PET/CT,

#1640 SDHB Mutation in a Young Patient with a Metastatic Paraganglioma of the Urinary Bladder

Introduction: Paragangliomas are rare tumors that arise from the sympathetic and parasympathetic ganglia that can possess an inherited trait.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Lambrescu I, Cima L, Leca B, Martin S, Fica S,

Keywords: paragangliomas, SDHB mutation,